Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
RICHMOND, Calif., May 11, 2017 -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, today announced the company plans to participate in the B. Riley & Co. Institutional Investor Conference in Santa Monica, California.
Ekso Bionics’ management is scheduled to present Wednesday, May 24, 2017 at 10:00 a.m. PDT. A live and archived webcast of the presentation will be available on the investors section of the company’s website at: www.eksobionics.com.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Media Contact: Carrie Yamond/Rajni Dhanjani 212-867-1788 [email protected] Investor Contact: Debbie Kaster 415-937-5403 [email protected]
